Immorta Bio Strengthens Board with Former EY Health Sciences Partner

  • Immorta Bio appointed Howard Brooks, former EY Health Sciences Partner, to its Corporate Board of Directors on May 21, 2026.
  • Brooks brings over three decades of experience in healthcare, life sciences, and biotechnology governance and strategy.
  • He will oversee governance, corporate strategy, financial matters, and capital-related initiatives for Immorta Bio.
  • Brooks is the second external board member, joining Russell Kaufman, venture partner at Pappas Capital.

Immorta Bio's appointment of Howard Brooks underscores its focus on strengthening governance and strategic leadership as it advances toward clinical trials. The move aligns with broader industry trends of biotech companies bolstering their boards with seasoned executives to navigate complex regulatory and financial landscapes. Brooks' background in capital markets and healthcare strategy positions Immorta Bio to better engage with investors and stakeholders as it pursues its mission of treating aging as a disease.

Governance Dynamics
How Brooks' extensive experience will influence Immorta Bio's strategic direction and capital markets engagement.
Clinical Progression
The pace at which Immorta Bio advances its dual-platform approach toward clinical development.
Investor Confidence
Whether the strengthened board will enhance investor trust and support future financing milestones.